Without having research capabilities, if you abandon MAPLE you are losing a Canadian industry; you are losing the opportunity for our post-graduate Ph.D. individuals, our academics, to have a very fruitful career in Canada. We are also abandoning our patients, because without having the ability to have medical isotope research in Canada, our patients' ability to access new and innovative research protocols will no longer be here, because all of that research may be south of the border.
So it is collateral damage and impact, and that's the importance of really ensuring that Canada does have a role to play in medical isotope production and in basic nuclear research as well, because these reactors are research and production units. We are focusing on medical isotopes, but we cannot abandon our research potential, and I'm very concerned about that.